docetaxel plus carboplatin with trastuzumab followed by trastuzumab
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
Comparator:
vs doxorubicin plus cyclophosphamide followed by docetaxel; vs docetaxel plus carboplatin with trastuzumab followed by trastuzumab;
Risk of bias:
low;
some concerns;
high;
NA;